PIRS
Income statement / Annual
Last year (2024), Pieris Pharmaceuticals, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Pieris Pharmaceuticals, Inc.'s net income was -$17.43 M.
See Pieris Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$42.81 M |
$25.90 M |
$31.42 M |
$29.32 M |
$46.28 M |
$29.10 M |
$25.28 M |
$5.83 M |
$2.93 M |
| Cost of Revenue |
$0.00
|
$41.80 M
|
$2.78 M
|
$2.37 M
|
$46.53 M
|
$55.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$1.01 M
|
$23.12 M
|
$29.05 M
|
-$17.21 M
|
-$8.72 M
|
$29.10 M
|
$25.28 M
|
$5.83 M
|
$2.93 M
|
| Gross Profit Ratio |
0
|
0.02
|
0.89
|
0.92
|
-0.59
|
-0.19
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$8.15 M
|
$41.80 M
|
$52.98 M
|
$66.66 M
|
$46.53 M
|
$55.00 M
|
$41.49 M
|
$22.29 M
|
$19.70 M
|
$8.24 M
|
| General & Administrative Expenses |
$5.94 M
|
$16.85 M
|
$16.39 M
|
$16.59 M
|
$16.71 M
|
$18.44 M
|
$18.44 M
|
$17.58 M
|
$8.89 M
|
$8.37 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.94 M
|
$16.85 M
|
$16.39 M
|
$16.59 M
|
$16.71 M
|
$18.44 M
|
$18.44 M
|
$17.58 M
|
$8.89 M
|
$8.37 M
|
| Other Expenses |
$0.00
|
$13.91 M
|
-$8.17 M
|
-$3.69 M
|
-$3.66 M
|
-$26.00 K
|
$1.80 M
|
-$2.10 M
|
$119.50 K
|
$10.91 K
|
| Operating Expenses |
$14.10 M
|
$72.57 M
|
$61.20 M
|
$79.56 M
|
$63.24 M
|
$73.44 M
|
$59.93 M
|
$39.87 M
|
$28.59 M
|
$16.61 M
|
| Cost And Expenses |
$0.00
|
$72.57 M
|
$61.20 M
|
$79.56 M
|
$63.24 M
|
$73.44 M
|
$59.93 M
|
$39.87 M
|
$28.59 M
|
$16.61 M
|
| Interest Income |
$0.00
|
$1.85 M
|
$721.00 K
|
$4.00 K
|
$511.00 K
|
$1.71 M
|
$1.96 M
|
$152.00 K
|
$2.32 K
|
$0.00
|
| Interest Expense |
-$3.89 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.95 M
|
$2.32 K
|
$184.65 K
|
| Depreciation & Amortization |
$0.00
|
$1.78 M
|
$2.78 M
|
$2.37 M
|
$2.13 M
|
$1.04 M
|
$570.00 K
|
$369.00 K
|
$361.38 K
|
$307.91 K
|
| EBITDA |
$0.00 |
-$22.76 M |
-$30.50 M |
-$43.37 M |
-$31.61 M |
-$26.12 M |
-$30.26 M |
-$14.23 M |
-$22.40 M |
-$13.37 M |
| EBITDA Ratio |
0
|
-0.53
|
-1.18
|
-1.38
|
-1.08
|
-0.56
|
-1.04
|
-0.56
|
-3.84
|
-4.56
|
| Operating Income Ratio |
0
|
-0.7
|
-1.68
|
-1.65
|
-1.16
|
-0.59
|
-1.06
|
-0.58
|
-3.9
|
-4.67
|
| Total Other Income/Expenses Net |
$0.00
|
$5.21 M
|
$10.20 M
|
$6.09 M
|
-$3.15 M
|
$1.69 M
|
$3.77 M
|
-$1.95 M
|
$122.00 K
|
-$173.74 K
|
| Income Before Tax |
-$17.43 M
|
-$24.54 M
|
-$33.28 M
|
-$45.74 M
|
-$37.07 M
|
-$25.47 M
|
-$27.07 M
|
-$16.54 M
|
-$22.64 M
|
-$13.85 M
|
| Income Before Tax Ratio |
0
|
-0.57
|
-1.28
|
-1.46
|
-1.26
|
-0.55
|
-0.93
|
-0.65
|
-3.88
|
-4.73
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$2.02 M
|
-$2.37 M
|
$164.00 K
|
-$1.71 M
|
-$312.00 K
|
$1.10 M
|
$161.97 K
|
$203.87 K
|
| Net Income |
-$17.43 M
|
-$24.54 M
|
-$31.25 M
|
-$43.37 M
|
-$37.23 M
|
-$23.76 M
|
-$26.75 M
|
-$17.65 M
|
-$22.80 M
|
-$14.06 M
|
| Net Income Ratio |
0
|
-0.57
|
-1.21
|
-1.38
|
-1.27
|
-0.51
|
-0.92
|
-0.7
|
-3.91
|
-4.8
|
| EPS |
-7.83 |
-21.8 |
-33.71 |
-53.75 |
-54.67 |
-37.54 |
-40.32 |
-32.14 |
-43.73 |
-32.7 |
| EPS Diluted |
-7.83 |
-21.8 |
-33.71 |
-53.75 |
-54.67 |
-37.54 |
-40.32 |
-32.14 |
-43.73 |
-32.7 |
| Weighted Average Shares Out |
$2.23 M
|
$1.13 M
|
$927.15 K
|
$806.84 K
|
$681.01 K
|
$632.81 K
|
$663.51 K
|
$549.14 K
|
$521.41 K
|
$429.91 K
|
| Weighted Average Shares Out Diluted |
$2.23 M
|
$1.13 M
|
$927.15 K
|
$806.84 K
|
$681.01 K
|
$632.81 K
|
$663.51 K
|
$549.14 K
|
$521.41 K
|
$429.91 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
